69038-74-0

Usage

Uses

Used in Fragrance and Flavoring Industry:
TERT-BUTYL-3-BROMOBENZOATE is used as a key ingredient in the formulation of fragrances and flavorings due to its appealing fruity scent, enhancing the sensory experience of various consumer products.
Used in Pharmaceutical Industry:
TERT-BUTYL-3-BROMOBENZOATE is utilized as an intermediate in organic synthesis for the preparation of pharmaceuticals, contributing to the development of new medications and therapeutic agents.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, TERT-BUTYL-3-BROMOBENZOATE serves as an intermediate in the synthesis of various agrochemicals, playing a role in the production of pesticides and other agricultural products to ensure crop protection and yield enhancement.

InChI:InChI=1/C11H13BrO2/c1-11(2,3)14-10(13)8-5-4-6-9(12)7-8/h4-7H,1-3H3

Upstream product

• 1711-09-7 3-bromobenzoyl chloride 
• 1907-33-1 lithium tert-butoxide 
• 108-36-1 1,3-dibromobenzene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 201230-82-2 carbon monoxide 
• 591-19-5 m-Bromoaniline 
• 75-65-0 tert-butyl alcohol 
• 585-76-2 m-bromobenzoic acid 
• 75-91-2 tert.-butylhydroperoxide 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 83766-88-5 2-tert-butoxypyridine 
• 865-47-4 potassium tert-butylate 
• 50-43-1 2,4,6-trichlorobenzoic acid 

Downstream Products

• 133776-51-9 3'-(tert-butoxycarbonyl)-2-aminobenzophenone 
• 247186-56-7 tert-butyl 3-formylbenzoate 
• 92146-82-2 tert-butyl 3-aminobenzoate 
• 901300-63-8 3'-hydroxymethyl-biphenyl-3-carboxylic acid tert-butyl ester 
• 721939-74-8 3'-azidomethyl-biphenyl-3-carboxylic acid 
• 901300-76-3 5-[(3'-azidomethyl-biphenyl-3-carbonyl)-amino]-pentanoic acid 
• 901300-65-0 6-[(3'-azidomethyl-biphenyl-3-carbonyl)-amino]-hexanoic acid 

Relevant academic research and scientific papers

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Silver/manganese dioxide nanorod catalyzed hydrogen-borrowing reactions and tert-butyl ester synthesis

Silver/manganese dioxide (Ag@MnO2) nanorods are synthesized and characterized by scanning electron microscopy, transmission electron microscopy, energy dispersive X-ray spectroscopy, X-ray powder diffraction, and X-ray photoelectron spectroscopy. It was discovered that Ag@MnO2 nanorods can realize hydrogen-borrowing reactions in high yields and are also effective for the synthesis of tert-butyl esters from aryl cyanides and tert-butyl hydroperoxide in a short period of time. Mechanistic experiments revealed that this catalytic system acts as a Lewis acid in hydrogen-borrowing reactions, while the synthesis of tert-butyl esters occurs through a radical pathway. This is the first report on the excellent catalytic activity of Ag@MnO2 nanorods as a catalyst.

A Zirconium Indazole Carboxylate Coordination Polymer as an Efficient Catalyst for Dehydrogenation-Cyclization and Oxidative Coupling Reactions

Rational ligand design is crucial for achieving widespread applications of coordination polymers. The preparation, structural characterisation, and catalytic applications of zirconium (IV) coordination polymer (Zr-IDA), which was derived from 1-(carboxymethyl)-1H-indazole-5-carboxylic acid are reported. The Zr-IDA catalyst contains porous and highly crystalline particles with a quasi-spherical morphology around 100 nm in size, and Zr was coordinated with both O and N as shown by FT-IR and XPS measurements. Importantly, the Zr-IDA catalyst shows great activity, selectivity and stability in the oxidative coupling of benzyl cyanides with tert-butyl hydroperoxide to afford tert-butyl peresters, and the dehydrogenation cyclization of o-phenylenediamines with aromatic alcohols to afford 1,2-disubstituted benzimidazole derivatives. Mechanistic investigations were carried out to study these reactions and the developed catalytic system in more detail.

A fast and practical synthesis of tert-butyl esters from 2-tert-butoxypyridine using boron trifluoride·diethyl etherate under mild conditions

A practical direct preparation of tert-butyl esters from 2-tert-butoxypyridine has been developed. This system features the use of boron trifluoride·diethyl etherate in toluene solvent to rapidly achieve the reaction at room temperature. Using this reaction protocol, a variety of tert-butyl esters were synthesized from several different carboxylic acids at high yields. This practical procedure provides a promising and effective approach to the protection of carboxylic acids with a tert-butyl group.

Metal-free radical aromatic carbonylations mediated by weak bases

We report a new method of metal-free alkoxycarbonylation. This reaction involves the generation of aryl radicals from arenediazonium salts by a very weak base (HCO2Na) under mild conditions. Subsequent radical trapping with carbon monoxide and alcohols gives alkyl benzoates. The conditions (metal-free, 1 equiv. base, MeCN, r.t., 3 h) tolerate various functional groups (I, Br, Cl, CF3, SF5, NO2, ester). Mechanistic studies indicate the operation of a radical aromatic substitution mechanism.

Synthesis of a Sterically Demanding Dispiropiperidine and Its Application in Monoamidodialkyl Zincate Complexes

The new sterically hindered piperidine analog, dispiro[cyclohexane-2,2′-piperidine-6′,2″-cyclohexane] (CPC(H), 2), and its N-methylated derivative CPC(Me) (3) were synthesized from commercially available starting materials in short steps. The N-lithiated amide LiCPC (4) was also isolated from 2 as a cyclictrimer in single crystals and showed slightly larger steric hindrance than that of lithium 2,2,6,6-tetramethylpiperidide (LiTMP) in the competitive methylation reaction with methyl trifluoromethanesulfonate. In addition, the heterobimetallic heteroleptic zincate complexes [Li(μ-NR2)(μ-Et)Zn(Et)] (NR2 = CPC, 5, and NR2 = TMP, 6) were obtained as THF- and TMEDA-coordinated monomer 5·(THF)2, 6·(THF)2, 5·TMEDA, and 6·TMEDA (THF = tetrahydrofuran, TMEDA = N,N,N′,N′-tetramethylethylenediamine). These molecular structures bearing different amido ligands in single crystals showed little structural differences from crystallographic studies. Diffusion-ordered spectroscopy (DOSY) revealed that the solution structures of the zincate complexes 5·(THF)2 and 6·(THF)2 only differ in the number of coordination THF molecules. In the deprotonation reactions with tert-butyl 3-bromobenzoate, the zincate complexes containing the CPC ligand [Li(μ-CPC)(μ-R)Zn(R)] (R = Et (5), tBu) showed moderately improved regioselectivity for the 6 position in comparison to those containing the TMP ligand [Li(μ-TMP)(μ-R)Zn(R)] (R = Et (6), tBu).

Highly selective and efficient conversion of aryl bromides to t-butyl benzoates with di-t-butyl dicarbonate

t-Butyl benzoates can be accessed from aromatic compounds bearing multiple halogen substituents via selective metal-halogen exchange with lithium tri-n-butylmagnesium ate complex followed by trapping with di-t-butyl dicarbonate.

Protease inhibitors

The present invention provides bis-aminomethyl carbonyl protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.